Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
The funds will be used to scale up existing operations and launch new products
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
